×
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
NASDAQ:MDGL

Madrigal Pharmaceuticals Stock Forecast, Price & News

$71.83
-3.47 (-4.61%)
(As of 06/28/2022 04:00 PM ET)
Add
Compare
Today's Range
$70.18
$76.11
50-Day Range
$58.04
$84.65
52-Week Range
$52.33
$105.93
Volume
222,024 shs
Average Volume
216,994 shs
Market Capitalization
$1.23 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$167.43
30 days | 90 days | 365 days | Advanced Chart

Receive MDGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MDGL Stock Forecast (MarketRank)

Overall MarketRank

2.45 out of 5 stars

Medical Sector

167th out of 1,433 stocks

Pharmaceutical Preparations Industry

63rd out of 685 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
Madrigal Pharmaceuticals logo

About Madrigal Pharmaceuticals (NASDAQ:MDGL)

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

MDGL Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:MDGL
CUSIP
87162T20
Employees
71
Year Founded
2011

Company Calendar

Last Earnings
5/09/2022
Today
6/28/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$167.43
High Stock Price Forecast
$220.00
Low Stock Price Forecast
$111.00
Forecasted Upside/Downside
+133.1%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
6 Analysts

Profitability

Net Income
$-241.85 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$11.47 per share

Miscellaneous

Free Float
12,022,000
Market Cap
$1.23 billion
Optionable
Optionable
Beta
1.29

Social Links















Madrigal Pharmaceuticals Frequently Asked Questions

Should I buy or sell Madrigal Pharmaceuticals stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Madrigal Pharmaceuticals stock.
View analyst ratings for Madrigal Pharmaceuticals
or view top-rated stocks.

What is Madrigal Pharmaceuticals' stock price forecast for 2022?

6 analysts have issued twelve-month target prices for Madrigal Pharmaceuticals' shares. Their MDGL stock forecasts range from $111.00 to $220.00. On average, they expect Madrigal Pharmaceuticals' share price to reach $167.43 in the next year. This suggests a possible upside of 133.1% from the stock's current price.
View analysts' price targets for Madrigal Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Madrigal Pharmaceuticals' stock price performed in 2022?

Madrigal Pharmaceuticals' stock was trading at $84.74 on January 1st, 2022. Since then, MDGL shares have decreased by 15.2% and is now trading at $71.83.
View the best growth stocks for 2022 here
.

When is Madrigal Pharmaceuticals' next earnings date?

Madrigal Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Madrigal Pharmaceuticals
.

How were Madrigal Pharmaceuticals' earnings last quarter?

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) released its earnings results on Monday, May, 9th. The biopharmaceutical company reported ($3.36) earnings per share for the quarter, beating analysts' consensus estimates of ($3.75) by $0.39. During the same period in the prior year, the business earned ($3.32) EPS.
View Madrigal Pharmaceuticals' earnings history
.

Who are Madrigal Pharmaceuticals' key executives?

Madrigal Pharmaceuticals' management team includes the following people:
  • Dr. Paul A. Friedman M.D., Chairman & CEO (Age 79, Pay $1.05M)
  • Dr. Rebecca A. Taub M.D., Founder, Chief Medical Officer, Pres of R&D and Director (Age 70, Pay $854.75k)
  • Mr. Alex G. Howarth, Sr. VP & CFO (Age 53, Pay $605.3k)
  • Mr. Brian J. Lynch J.D., Sr. VP & Gen. Counsel (Age 60, Pay $699.28k)
  • Mr. Remy Sukhija, Sr. VP & Chief Commercial Officer (Age 50, Pay $720.07k)
  • Dr. Kianoush Motesharei Ph.d., Sr. VP of Bus. & Corp. Devel. (Age 52)
  • Mr. Edward Chiang, Sr. VP of Clinical & Technical Operations
  • Mr. Thomas W. Hare, Sr. VP of Clinical Management
  • Dr. Robert E. Waltermire Ph.D., Chief Pharmaceutical Devel. Officer (Age 58)
  • Dr. Stephen Dodge M.B.A., Pharm.D., Sr. VP of Global Medical Affairs

What other stocks do shareholders of Madrigal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Exelixis (EXEL), Advaxis (ADXS), Viking Therapeutics (VKTX), Sangamo Therapeutics (SGMO), Amarin (AMRN), CRISPR Therapeutics (CRSP), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT) and Gilead Sciences (gild).

What is Madrigal Pharmaceuticals' stock symbol?

Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."

Who are Madrigal Pharmaceuticals' major shareholders?

Madrigal Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.11%), BlackRock Inc. (5.59%), Wellington Management Group LLP (5.27%), Deep Track Capital LP (4.60%), State Street Corp (4.48%) and Federated Hermes Inc. (2.00%). Company insiders that own Madrigal Pharmaceuticals stock include Bay City Capital Llc and Fred B Craves.
View institutional ownership trends for Madrigal Pharmaceuticals
.

Which major investors are selling Madrigal Pharmaceuticals stock?

MDGL stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Goldman Sachs Group Inc., Citigroup Inc., Parkman Healthcare Partners LLC, Group One Trading L.P., Northern Trust Corp, Metropolitan Life Insurance Co NY, and Royal Bank of Canada. Company insiders that have sold Madrigal Pharmaceuticals company stock in the last two years include Bay City Capital Llc, and Fred B Craves.
View insider buying and selling activity for Madrigal Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Madrigal Pharmaceuticals stock?

MDGL stock was acquired by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Deep Track Capital LP, State Street Corp, Vanguard Group Inc., Jane Street Group LLC, SG Americas Securities LLC, Dimensional Fund Advisors LP, and Campbell & CO Investment Adviser LLC.
View insider buying and selling activity for Madrigal Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Madrigal Pharmaceuticals?

Shares of MDGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Madrigal Pharmaceuticals' stock price today?

One share of MDGL stock can currently be purchased for approximately $71.83.

How much money does Madrigal Pharmaceuticals make?

Madrigal Pharmaceuticals (NASDAQ:MDGL) has a market capitalization of $1.23 billion. The biopharmaceutical company earns $-241.85 million in net income (profit) each year or ($14.650010) on an earnings per share basis.

How many employees does Madrigal Pharmaceuticals have?

Madrigal Pharmaceuticals employs 71 workers across the globe.

When was Madrigal Pharmaceuticals founded?

Madrigal Pharmaceuticals was founded in 2011.

How can I contact Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The official website for Madrigal Pharmaceuticals is www.madrigalpharma.com. The biopharmaceutical company can be reached via phone at (484) 380-9263, via email at [email protected], or via fax at 781-274-8228.

This page (NASDAQ:MDGL) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.